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Autoantibodies to type VII collagen are associated 
with the blistering diseases epidermolysis bullosa 
acquisita and bullous systemic lupus erythematosus. 
We showed previously that these autoantibodies rec-
ognize epitopes within the noncollagenous (NCt) 
region of type VII collagen. That region is composed 
of fibronectin type III homology units that may con-
tribute to intermolecular cross-linking and basement 
membrane adhesion functions of type VII collagen. 
In this study, we defined the specific amino acid 
sequences recognized by these autoantibodies. By 
fusion protein analysis, sera from patients with epi-
dermolysis bullosa acquisita and bullous lupus were 
found to react with two regions within the fourth 
(E-t) and eighth (E-2) fibronectin homology repeats, 
each consisting of approximately tOO amino acids. 
Affinity purification studies showed E-t and E-2 to be 
independent and non-cross-reactive epitope regions. 
These regions were probed further by enzyme-linked 
ype VII collagen (C7) is an epithelial basement 
membrane protein composed of three identical alpha 
chains, each consisting of an amino-terminal 14S-kD 
noncollagenous (NC1) domain and a 14S-kD car-
boxyl-terminal collagenolis domain [1,2]. 
Gammon et al [3] cloned cDNA for C7 that encoded the majority 
of the NC1 domain. Analysis of the deduced amino acid sequence 
revealed motifs characteristic of other multidomain extracellular 
matrix (ECM) proteins that contribute to tissue-specific organiza-
tion of the ECM. In particular, the NC1 domain was found to 
consist of sequential fibronectin type III (FN3 )-like repeats and an 
area homologous to the A-2 domain of von Willebrand factor 
[3-6]. Studies of the FN3 and vonWillebrand A domain homology 
regions of other matrix proteins have demonstrated the capability of 
these proteins to bind different types of collagen, and have sug-
gested that they may mediate significant protein-protein interac-
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immunosorbent assay analysis of overlapping oc-
tapeptide sets derived from the amino acid sequences 
of E-t and E-2. The results showed two reactive, 
closely associated octapeptide sequences within each 
region, both lying in amphipathic portions of fi-
bronectin type III homology repeats. These studies 
identify short peptide sequences within the NCt do-
main of type VII collagen that are targeted indepen-
dently by autoantibodies. These sequences may play 
a direct role in determining the properties of type VII 
collagen that influence adhesion between this mole-
cule and other basement membrane proteins, and 
their alteration by antibody binding may be the 
immunopathogenic event underlying epidermolysis 
bullosa acquisita and bullous lupus. Key words: epider-
molysis bullosa acquisita/bullous systemic lupus erythemato-
sus/autoimmunity/anchoring fibrils. ] Invest Dermatol 104: 
231-235, 1995 
tions [7-10]. These are the same characteristics that have been 
attributed to the C7 NC1 domain. 
Epidermolysis bullosa acquisita (EBA) and bullous eruption of 
systemic lupus erythematosus (bullous SLE) are autoimmune blis-
tering diseases characterized by circulating and tissue-bound IgG 
autoantibodies to the epithelial basement membrane. It has been 
demonstrated that these autoantibodies have specificity for C7 
[11,12]. It also has been shown by electron microscopy that EBA 
and bullous SLE result from epidermal-dermal separation d~e to 
lamina-densa-dermal dysadhesion [13,14]. This suggests that these 
antibodies directed against the principal structural components 
responsible for maintaining lamina-dens a- dermal adhesion may 
playa role in the pathogenesis of these diseases. 
In the current study, we used recombinant fusion proteins and 
synthesis of sequential, overlapping octapeptides corresponding to 
the NC1 domain to localize more precisely the immunodominant 
autoantibody epitopes of C7. By mapping the specific areas of 
autoantibody interaction with the C7 molecule, we hoped to elucidate 
a mechanism of immunopathogenesis for EBA and bullous SLE, as 
well as gain insight into which areas of this molecule are crucial to its 
functional integrity as a lamina-densa-dermal anchor. Knowledge of 
specific immunologically reactive peptide sequences also would allow 
comparison of these areas to protein sequence data bases to search for 
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possible foreign protein immunogens that could support a theory of 
molecular mimicry in explaining autoantibody production in patients 
with EBA and bullous SLE. 
MATERIALS AND METHODS 
DNA The source of DNA fragments for fusion protein expression was a 
previously described partial C7 cDNA (CVII-l) [3]. It encodes an estimated 
75% of the NC1 domain beginning downstream of thel 5' start site and 
ending at the beginning of the collagenous domain. It encodes 7 112 sequential 
FN3 repeats of 90 amino acids each, followed by a von Wille brand factor A 
domain homology region of 190 amino acids [3]. DNA corresponding to 
different regions of CVIl-l was prepared for cloning by restriction endonucle-
ase digestion and DNA amplification by the polymerase chain reaction. 
Fusion Proteins DNA fragments corresponding to the regions of NCl 
desired for expression were cloned into pGex-2T (Pharmacia LKB Biotech-
nology, Piscataway, NJ) per the supplier's protocol. pGex-2T glutathione-
S-transferase fusion proteins were expressed inJMI09 (DE3) Escherichia coli 
cells after addition of isopropyl-{3-D-thiogalactopyranoside to log phase 
cultures. Recombinant clones were screened by sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) of bacterial lysates for 
expression of fusion protein of predicted mass. Glutathione transferase 
fusion proteins were affinity-purified by absorption on glutathione sepha-
rose (pharmacia LKB Biotechnology) and assayed by SDS-PAGE. 
Enzyme-Linked Immunosorbent Assay (ELISA) Affinity-purified 
glutathione transferase fusion proteins were diluted in 0.1 M carbonate 
buffer, pH 9.6, and incubated overnight at 4°C in 96-well polystyrene 
micro titer plates (Costar, Cambridge, MA). The wells were washed with 
phosphate-bu1fered saline, pH 7.4, containing 0.05% Tween 20 and 0.25% 
bovine serum albumin (PBS-Tween-BSA), and blocked with PBS-Tween-
BSA. The wells were incubated with sera diluted in PBS-Tween-BSA, then 
washed with PBS-Tween-BSA. After washing, antibody binding was de-
tected using anti-human alkaline phosphatase-conjugated anti-IgG second-
ary antibody (Sigma, St. Louis, MO) and developed with p-nitrophenyl 
phosphate [15]. OD 405 readings for each well were taken with a micro titer 
plate reader (Molecular Devices, Menlo Park, CA) . 
Affinity Purification of Sera Affinity-purified glutathione transferase 
fusion proteins were diluted in 1 % BSA and incubated overnight at 4°C with 
nitrocellulose paper (Schleicher & Schuell, Keene, NH) in a petri dish. This 
was washed extensively with PBS, pH 7.4, containing 0.05% Tween 20. 
Patient sera were diluted in 1 % BSA and incubated with the nitrocellulose 
for 2 h at room temperature, then overnight at 4°C on a rotary shaker. The 
diluted sera were then decanted and saved as "post-absorbed" sera. The 
fusion protein-specific antibodies were eluted off the nitrocellulose with 
0.2 M glycine, neutralized, and concentrated. 
Synthesis of Pep tides Pep tides were synthesized on polystyrene rods in 
the configuration of a 96-well micro titer plate by the method of Geysen et 
af [16]. The peptide sequences of the E-l and E-2 suspected epitope regions 
were synthesized as octapeptides overlapping by seven amino acids (see Fig 
2). This synthesis was carried out according to the kit manufacturer's 
instructions (Cambridge Research Biochemicals, Wilmington, DE). Patient 
sera were analyzed for binding to these octapeptides using a modified ELISA 
technique. The synthetic peptides were precoated with 2% BSA-0.05% 
Tween 20-PBS for 1 h at room temperature. Patient sera were diluted in 
BSA-Tween-PBS and incubated for 1 h with the polyethylene rods bearing 
the synthetic peptides. The rods then were washed extensively in 0.01 M 
PBS, and antibody binding was detected using an anti-human peroxidase-
conjugated anti-lgG secondary antibody (Sigma), which was developed 
with 2,2' -azino-bis-(3-ethylbenzthiazadine-6-sulfonic acid) (Sigma). After 
1 h incubation in this substrate, the OD 405 of the incubation wells was 
measured in a micro titer plate reader (Molecular Devices). 
The antibodies bound to the synthetic peptides were removed per the 
manufacturer's instructions (Cambridge Research Biochemicals) , and the 
polyethylene rod-octapeptide system was reused. 
Affinity Purification of Sera Using Synthetic Peptide The decapep-
tide VPRAQGFLLH was synthesized by Multiple Peptide Systems (San 
Diego, CA). Using a kit supplied by this company, we anchored this peptide 
to a solid resin for affinity purification of patient sera. Anti-VPRAQG-
FLLH-specific antibodies were isolated from patient sera according to the 
protocol supplied with the kit. 
Indirect Immunofluorescence (IIF) Assay Affinity-purified patient 
sera were assayed by IIF using 1.0 M sodium-chloride-split normal human 
skin as substrate. This procedure has been described previously [17]. 
Antisera Sera were obtained from EBA and bullous SLE patients. All sera 
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were shown to contain autoantibodies to the epithelial basement membrane 
of stratified squamous epithelia by IIF on 1.0 M NaCI-split skin. All sera 
contained antibodies to the dermal side of split skin and reacted with tissue 
C7 or proC7 by Western immunoblotting, as described previously [3,18]. 
Control sera were obtained from normal humans and from bullous-
pemphigoid patients who have anti-basement membrane antibodies that 
target hemidesmosome-associated antigens. 
RESULTS 
Autoantibodies Directed Against Type VII Collagen Rec-
ognize Two Distinct, Non-Cross-Reactive Epitopes Pre-
vious data suggested the presence of two epitope regions within the 
NC1 domain ofC7: E-1, composed of295 amino acids correspond-
ing to the first 884 base pairs of the NC1 cDNA; and E-2, 
composed of 207 amino acids corresponding to base pairs 1372-
1992 of the eDNA (Fig 1). Three EBA sera and one bullous SLE 
sample were affinity-purified against the immobilized fusion pro-
teins E-1 and E-2 as described. This resulted in purified, epitope-
specific anti-E-1 and anti-E-2 antibody populations, as well as 
post-absorbed fractions of sera devoid of these antigen-specific 
populations of antibodies. ELISA analysis of these sera revealed the 
following. Affinity-purified anti-E-1 sera reacted strongly with E-1 
fusion protein but negligibly with E-2 fusion protein in three of 
three EBA sera and one of one bullous SLE serum. · Similarly, 
affinity-purified anti-E-2 sera reacted with E-2 fusion protein but 
not with E-1 fusion protein for all sera. Post-absorbed serum 
fractions demonstrated a marked decrease in the degree of their 
reactivity with the fusion protein used for their purification, but 
showed minimal or no change in the degree of reactivity with the 
other epitope protein. These data are summarized in Table I. 
These results suggest the existence of two distinct, non- cross-
reactive epitopes (represented by fusion proteins E-1 and E-2) 
within the NC1 region of C7. 
Affinity-purified anti-E-1 and anti-E-2 antibodies were assayed 
by IIF using NaCI-split human neonatal foreskin as substrate. All 
four sera demonstrated linear staining along the dermal side of the 
split for both anti-E-1 and anti-E-2 antibodies, the same pattern 
that is characteristic of the whole EBA and bullous SLE sera in this 
assay. As expected, the post-absorbed fractions of these sera 
revealed a decrease in IIF titer with respect to their parent sera. 
Three of three EBA sera and one of one bullous SLE serum 
demonstrated complete extinction of immunofluorescence after 
removal of both anti-E-1-specific and anti-E-2-specific antibody 
populations by absorption (Table II). This is evidence that these 
Figure 1. Schematic diagram demonstrating the areas of the Net 
domain represented by our fusion proteins. The cDNA encodes 7.5 
FN3 homology repeats starting from the 5' end and extending to a single 
region of von Wille brand factor A domain homology at the 3' end. The 
fusion proteins are depicted by bars containing either + + + or - - - , 
indicating their reactivity or lack of reactivity, respectively, with patient sera 
in ELISA. E-1 is 295 amino acids (AA) encoded by the first 884 hase pairs 
(BPs) of the cDNA; E-1A, 109 AA, BPs 0-327; E-IB, 224 AA, BPs 0-673; 
E-1C, 174 AA, BPs 405-927. E-2 is 207 amino acids encoded by base pairs 
1372-1992; E-2A, 99 AA, BPs 1372-1665; E-2B, 34 AA, BPs 1664-1765. 
The bottom bar represent s the primary structure of the NC1 domain, in which 
cross-hatching delineates areas of consensus recognition by autoimmune sera. 
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Table I. ELISA Reactivity of EBA and Bullous SLE 
Affinity-Purified and Post-Absorbed Sera with E-1 and E-2 
Fusion Proteins 
Patient sera 
EBA-1 
EBA-2 
EBA-3 
BSLE-1 
Affinity-purified sera 
EBA-1 anti-E-1 
EBA-2 anti-E-1 
EBA-3 anti-E-1 
BSLE-1 anti-E-1 
EBA-l anti-E-2 
EBA-2 anti-E-2 
EBA-3 anti-E-2 
BSLE-1 anti-E-2 
Post-absorbed fraction of 
sera purified against E-1 
EBA-1 
EBA-2 
EBA-3 
BSLE-1 
Post-absorbed fraction of 
sera purified against E-2 
EBA-1 
EBA-2 
EBA-3 
BSLE-1 
a BSLE, bullous SLE. 
E-1 Fusion Protein 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
E-2 Fusion Protein 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
fusion protein epitopes (E-l and E-2) correspond to C7 epitopes in 
native human skin and, at least for one bullous SLE and three EBA 
sera, account for the full extent of anti-C7 autoantibody binding. 
Analysis of E-1 and E-2 Using Small Recombinant Fusion 
Proteins Within These Domains To localize further epitopes 
within the relatively large E-l and E-2 regions, we created smaller 
fusion proteins representative of areas within these two broad 
domains. For E-2, we constructed fusion proteins E-2A, corre-
sponding to the first 99 amino acids of this 207 -amino acid region; 
and E-2B, corresponding to amino acids 100-133 (Fig 1). Auto-
immune EBA and bullous SLE sera were reacted with these fusion 
proteins by ELISA. E-2A was recognized by 10 of 12 EBA and 
seven of seven bullous SLE sera; E-2B was recognized by zero of 
five EBA and zero of four bullous SLE sera (Table III). Control 
sera from four normal humans and two patients with bullous 
pemphigoid were tested in all assays and showed no reactivity with 
any of the fusion protein fragments. These data suggest that the 
predominant E-2 epitope lies within the 99-amino acid E-2A region. 
Anti-E-2A-specific antibody populations were affinity-purified 
from one EBA and one bullous SLE serum sample using immobi-
lized fusion protein. ELISA analysis of these anti- E-2A-specific, 
affinity-purified sera and their post-absorbed fractions revealed the 
Table II. Results of IIF Assays of Autoimmune Sera 
Before and After Absorption Against E-1 and E-2 Fusion 
Proteins Using NaCI-Split Human Skin as Substrate 
IIF of Native Serum 
EBA-1 
EBA-2 
EBA-3 
BSLE-1 
a BSLE, bullous SLE. 
1:80 
1:80 
1:160 
1:40 
IIF of Serum 
Absorbed Against E-1 
and E-2 
o at 1:5 
o at 1:5 
o at 1:5 
o at 1:5 
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Table III. ELISA Reactivity of EBA and Bullous SLE 
Sera with Fusion Protein Fragments 
Fusion Protein EBA Sera BSLE Seraa 
E-1A 0/7 0/5 
E-1B 4/6 2/4 
E-1C 4/5 0/4 
E-2A 10/12 7/7 
E-2B 0/5 0/4 
a BSLE, bullous SLE. 
following. The affinity-purified anti-E-2A sera reacted with E-2A 
and E-2 fusion protein but not with E-l fusion protein. Post-
absorbed fractions of both sera, devoid of anti-E-2A antibodies, 
showed negligible reactivity with E-2A and E-2. Finally, the affinity-
purified anti-E-2A sera stained NaCI-split hwnan skin in an IIF assay 
with the linear dermal pattern characteristic of anti-C7 antibodies. 
These data suggest that the E-2 epitope is confined to the E-2A 
region and that antibodies with this epitope specificity also recog-
nize native C7 in human skin. Thus, we have identified an 
immunologically significant epitope within the NCl domain of C7. 
A similar evaluation of E-l was performed by producing fusion 
proteins corresponding to areas within this epitope: E-1A, corre-
sponding to the first 109 amino acids ofE-l; E-1B, containing the 
first 224 amino acids; and E-1C, containing amino acids 136-309 
encoded by the NCl cDNA (Fig 1). By ELISA, zero of seven EBA 
and zero of five bullous SLE sera reacted with E-1A; four of six 
EBA and two of four bullous SLE sera reacted with E-1B (Table 
III) . Control sera from four normal humans and two patients with 
bullous pemphigoid were tested in all assays and showed no 
reactivity with any of the fusion protein fragments. 
For a single reactive epitope region to produce these results, it 
would have to lie within the area shared by E-1B and E-1C, but 
outside the area of E-1A. Thus, we consider this 11s-amino acid 
region to represent the predominant E-l epitope. 
Anti-E-l C-specific antibody populations were isolated by affin-
ity purification of two EBA patient sera. By ELISA, these affinity-
purified anti-E-l C sera revealed strong reactivity with both E-l C 
and E-l fusion proteins. There was no reactivity of these sera with 
E-2. Post-absorbed sera from these purifications, devoid of anti-E-
1 C-specific antibody populations, demonstrated only minimal re-
activity with E-l and E-1C fusion proteins. In an IIF assay, the 
affinity-purified anti-E-1C sera stained NaCI-split human skin with 
the linear dermal pattern characteristic of anti-C7 antibodies. 
Thus, we have localized the predominant C7 epitopes to two 
small, distinct areas within the NCl domain of that molecule: E-l , 
a llS-amino acid region located along FN3 repeat number 4; and 
E-2, a 99-amino acid region within FN3 repeat number 8. 
Use of Synthetic Peptides to Localize More Precisely the 
E-1 and E-2 Epitopes Once the epitopes were narrowed to 
these relatively short segments (E-l, 115 amino acids; E-2, 99 
amino acids), we used peptide synthesis to investigate these regions 
further. Using a commercially available kit, sequential, overlapping 
octapeptides, derived from the amino acid sequences of these two 
short reactive segments, were synthesized and anchored to poly-
ethylene rods arranged in the configuration of a 96-well micro titer 
plate (Fig 2). This method allows immunologic analysis of every 
possible 8-amino acid stretch within the peptide, enabling precise 
localization of specific areas of high-affinity antibody binding. 
These peptide sets were analyzed by ELISA for reactivity with EBA 
and bullous SLE sera (Fig 3). 
For the E-2 epitope, octapeptides covering the 99-amino acid 
sequence of the E-2A fusion protein were synthesized. By ELISA, 
four of the five sera tested (two of three EBA and two of two 
bullous SLE) demonstrated the most vigorous response to the 
octapeptide NH2 - VPRAQGFL, and the fifth serum reacted most 
strongly with a partially overlapping peptide, NH2-LPWEPVPR. 
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Figure 2. Diagram depicting the method of synthesis of sequential 
overlapping octapeptides for individual ELISA assay. The amino acid 
sequence of the E-2A fusion protein is displayed at the top of the figure. 
Brackets demonstrate how octapeptide segments of that sequence are synthe-
sized and anchored to polyethylene rods. Each rod bears a unique peptide that 
can be assayed by ELISA, allowing determination of serum reactivity with every 
possible eight-amino acid stretch within the sequence. 
Lesser degrees of recognition were evident for the same four of five 
against a second region of sequential, overlapping peptides-NH2 -
LGTLHVVQ, NH2-GTLHVVQR, and NHz-TLHVVQRG-
which are slightly upstream of the primary region of antibody 
recognition. Control sera from five normal humans and one 
bullous-pemphigoid patient demonstrated varying degrees of non-
specific background activity against this E-2A set of octapeptides, 
but no pattern of specific sequence recognition. Affinity-purified 
anti-E-2A sera from one EBA and one bullous SLE patient strongly 
recognized these same two regions. From this, we conclude that the 
octapeptide NH2 - VPRAQGFL represents the primary antigenic 
epitope of E-2A, with the upstream sequence of NH2-LGTLHV-
VQRG contributing to a lesser epitope (Fig 4). Thus, we have 
defined the E-2 epitope to the level of amino acid specificity. 
For the E-l epitope, octapeptides were synthesized representing 
the first 100 amino acids of the llS-amino acid segment shown to 
contain the reactive epitope. By ELISA, five of six EBA and two of 
two bullous SLE sera reacted with the same two areas within this 
region (Fig 3). The one EBA serum not demonstrating this pattern 
also reacted poorly with the E-l fusion protein fragment, and by IIF 
is known to have a low titer of anti-BMZ antibody. The octapep-
tide NH2-RVSWPVP and its overlapping neighbors appear to 
represent the predominant epitope, and the slightly downstream 
octapeptide NH2-IIWRSTQG and its overlapping neighbors rep-
resent a second epitope of less avidity (Fig 4). Affinity-purified 
anti-E-l sera from one EBA and one bullous SLE patient reacted 
with this same specific pattern. Control sera from five normal 
humans and one bullous-pemphigoid patient demonstrated varying 
degrees of nonspecific background activity against this E-l set of 
octapeptides, but no pattern of specific sequence recognition. 
The predominant E-2 epitope octapeptide, NH2 - VPRAQGFL, 
was synthesized in milligram quantities and attached to a solid resin for 
affinity purification of autoimmune patient sera. Anti-VPRAQGFL 
sequence-specific antibodies were affinity-purified from two EBA and 
one bullous SLE sera and tested in an IIF assay against salt-split human 
skin. All sera stained the dermal side of the split skin with the linear 
pattern characteristic of the native sera. One normal human serum 
sample and one from a patient with bullous pemphigoid were purified 
with the NH2 - VPRAQGFL affinity-purification column as controls. 
Neither of these controls stained salt-split skin in IIF assays. This result 
demonstrates that the defined epitope sequence for E-2 represents the 
native epitope in human skin. 
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DISCUSSION 
In the present study, we have demonstrated the presence of two 
distinct, non-cross-reactive autoepitopes within the NCl domain 
of C7. We have localized these epitopes to paired, short peptide 
sequences lying within the FN3 repeat homology region of the 
NCl domain. Using epitope-specific, affinity-purified EBA and 
bullous SLE patient sera in IIF assays on human skin substrate, we 
have shown that the epitopes we have characterized represent the 
immunodominant epitopes of C7 in native human skin. 
Immunologic investigation of C7 has focused on the 14S-kD 
amino terminal NCl domain of the molecule, as early data 
demonstrated that patient autoantibodies recognized this region in 
proteolytically cleaved C7 [11]. In addition, the putative role of the 
NCl domain in mediating the protein-protein interactions respon-
sible for the adherence of anchoring fibrils to other ECM compo-
nents made this area attractive to investigations ofblistering-disease 
pathogenesis. Using fusion protein fragments representing most of 
the NCl domain, we demonstrated previously that the autoanti-
bodies from EBA and bullous SLE patients bind to the FN3 
homology region of the NCl domain [19]. These same studies 
showed no reactivity of patient autoantibodies with a fusion protein 
corresponding to the von Wille brand factor A domain homology 
region. In the current study, we focused on further exploring 
antibody reactivity with the FN3 homology region. 
Elucidation of the specific peptide sequences of the E-l and E-2 
epitopes allowed us to localize them precisely within the NCl 
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Figure 3. ELISA reactivity of EBA serum with the synthetic octa-
peptides representing the E-l and E-2A fusion proteins. The numbers 
along the abscissa indicate individual octapeptides (1 = amino acids [AAs] 
1-8 of the sequence; 2 = AA 2-9; 3 = AA 3-10; etc.), and the bars depict 
the degree of reactivity (as measured by OD 405) of that octapeptide with 
the patient serum. For both E-1 (A) and E-2 (B), there are two distinct areas 
of reactivity with m st autoimmune sera tested. These are shown in these 
representative ELISAs. 
VOL. 104, NO.2 FEBRUARY 1995 
A 
E-1 
E-2 
B 
TEYRlTlYTllEGHEYATPATYYPTGPElPYSPYTDlQATDYPGQRY 
110 130 150 
<-m:-:rn~~·ERTlYlPGSQTAfDlDDYQAGlSYTYRYSA 
190 209 
TDSAEIRGlEGGYSYSYRYTAlYGDREGTPYSIYYTTPPEAPPAlGTlHYY~ 
458 480 500 ::::::::::::n:::1::::1:  
:;!:::::::;:;:;:;:;!;:;:;: 
RGEHSlRlRWEPIYPIMUGfllHWQPEGGQEgSRYlGPElSSYHlD 
520 ::::::;:H::::::H::: 540 554 
A DOMAIN 
HOMOLOGY 
REGION 
Figure 4. Localization of immunoreactive peptide sequences 
within epitopes E-t and E-2. and their location within the FN3 
repeats of the Net domain. A) The amino acid sequences of the E-1 and 
E-2 regions synthesized as overlapping octapeptides for ELISA testing of 
autoimmune sera . Boxed areas depict the octapeptides recognized most 
strongly by the sera tested. There are two neighboring reactive sequences 
for both E-1 and E-2. B) Localization of these sequences within the FN3 
repeat homology region of the NC1 domain: E-1 along repeat no. 4, and 
E-2 along repeat no. 8. Alignment is based on invariant tryptophan and 
tyrosine residues using the GCG software package. Note their location 
along the turn of the B-pleated sheet of the FN3 repeats. Using the method 
oflocal hydrophilicity calculation of Hopp and Woods l20], these epitope 
regions were both shown to be very hydrophobic. 
domain. The two short peptide epitopes ofE-1 were found to reside 
in FN3 repeat number 4 in a hydrophobic region along a tum of the 
B-pleated sheet structure of this repea t. It is interesting tha t the two 
short peptide epitopes ofE-2 were similarly shown to reside within 
an FN3 repeat (no. 8) in a hydrophobic region along the tum of the 
B-pleated sheet (Fig 4). This unique paired location of these 
epitopes indicates that these areas of the C7 molecule may be 
structurally vital to the functional integrity of C7 as a matrix compo-
nent. One can easily imagine that antibody binding along these 
B-pleated sheet turns could disrupt the secondary structure of the FN3 
repeat area, which in turn could lead to altered matrix-binding 
properties of this region or an inability of such distorted C7 molecules 
to aggregate appropriately into anchoring fibrils. Either of these 
mechanisms could lead to lamina-densa-dermal dysadhesion through 
impairment of anchoring-fibril function and result in an immuno-
pathogenic event that would explain the blistering ofEBA and bullous 
SLE. These epitopes also may represent areas of molecular abnormality 
in patients with inherited forms of dystrophic epidermolysis bullosa, in 
which structural alterations are mediated not through antibody bind-
ing, but by improper protein synthesis due to errors in DNA coding for 
these regions. These studies add to the mounting evidence that the 
NC1 domain ofC7 and, in particular, the region ofFN3 homology is 
significant in mediating the interaction between anchoring fibrils and 
other matrix proteins. 
Knowledge of these specific autoepitope sequences also allowed 
us to compare them to a protein sequence data bank to search for 
molecular homology that could substantiate a claim for molecular 
mimicry as a mechanism of immunogenicity in EBA and bullous 
SLE. A homology search of the Swissprot data base revealed no 
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significant homology between the main autoreactive sequences and 
any sequences in that data base. 
Because of the limitations of the experimental techniques em-
ployed, our investigation was confined to identifying the major 
areas of antigenicity within the NC1 domain of C7. More specific 
serum absorption studies using synthetic peptides to isolate antigen-
specific antibody populations for each epitope sequence would 
allow more precise definition of C7 antigenicity. Such antigen-
specific absorption studies are necessary to confirm our suspicion 
that the epitopes we have identified do indeed correspond to the 
full complement of autoantibodies to native C7. These investiga-
tions should be pursued as a part of future projects attempting to 
clarify CTs role as an autoantigen. 
This work was supported in part by grants A R07369, AR30475, and AR10546 
fronl the National Institutes of H ealth . 
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